This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/drug/DB04812/identifier/chemspider/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04812/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n7http://linked.opendata.cz/resource/drugbank/drug/DB04812/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB04812/identifier/drugbank/

Statements

Subject Item
n2:DB04812
rdf:type
n3:Drug
n3:description
The use of benoxaprofen, formerly marketed as Oraflex tablets, was associated with fatal cholestatic jaundice among other serious adverse reactions. The holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982.
n3:group
withdrawn
owl:sameAs
n9:DB04812 n12:DB04812
dcterms:title
Benoxaprofen
adms:identifier
n6:36518 n7:46508496 n10:DB04812 n11:39941
n3:synonym
Benoxaprofenum (1)-2-(4-Chlorophenyl)benzoxazole-5-propionic acid 2-[2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid 2-(4-Chlorophenyl)-alpha-methyl-5-benzoxazoleacetic acid Benoxaprofene 2-(2-(4-Chlorophenyl)-1,3-benzoxazol-5-yl)propanoic acid DL-benoxaprofen Benoxaprofeno
n3:synthesisReference
Evans, D., Dunwell, D.W. and Hicks, A.; US. Patent 3,912, 18; October 14, 1975; assigned to Lilly Industries Ltd. Evans, D., Dunwell, D.W. and Hicks, T.A.; U.S. Patent 3,962,441; June 8, 1976; assigned to Lilly Industries, Ltd. Evans, D., Dunwell, D.W. and Hicks, T.A.; US. Patent 3,962,452; June 8, 1976; assigned to Lilly Industries, Ltd.
n14:hasConcept
n15:M0058178
n3:IUPAC-Name
n4:271B55B9-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B55BF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B55BE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B55BB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B55BC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B55BD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B55B7-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B55B5-363D-11E5-9242-09173F13E4C5 n4:271B55B8-363D-11E5-9242-09173F13E4C5 n4:271B55D0-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B55B6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B55C5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B55C6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B55C0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B55C1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B55C3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B55C2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B55C4-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
51234-28-7
n3:category
n3:Bioavailability
n4:271B55CB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B55CD-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B55CE-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B55CF-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B55CA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B55C9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B55CC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B55BA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B55C7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B55C8-363D-11E5-9242-09173F13E4C5